The NOCEDP is a clinical research program designed to identify those women who are at increased risk for developing ovarian cancer and to apply new research and tests, related to the ovaries, to help detect ovarian cancer at an early stage.

The program combines the expertise of gynecologic oncology, medical oncology, advanced-practice oncology nursing, genetics, ultrasonography, biochemistry, and molecular biology to offer a comprehensive early detection program for women at risk of developing ovarian cancer.

While the presence of one or more of the following risk factors may increase a woman’s risk for developing ovarian cancer, it does not necessarily mean that she will.

• personal history of breast, colon or urinary cancer
  
• one or more first-degree relatives (mother, sister, daughter) who have ovarian cancer
  
• multiple family members with breast and/or ovarian cancer
  
• uninterrupted ovulation (infertility, never used birth control pills or never pregnant)
  
• the use of fertility drugs such as Clomid and Pergonal for more than one year
  
• age 40 or older; as with most cancers, a woman’s chances of developing ovarian cancer increases with age. The average age of developing ovarian cancer is 58, with the highest incidence of occurrence between the ages of 70 and 79.

What happens during a visit to the NOCEDP?

Women who qualify for the program will receive an extensive personal and family medical history questionnaire to complete prior to the initial visit. First-time appointments will last approximately two hours, with more time allotted if necessary. Return appointments will last approximately one and a half hours, with more time allotted if necessary.

This research study is limited to the early detection of ovarian cancer. Therefore, all participants entering the program must have a referring physician who will provide routine gynecologic care, such as internal examination, Pap tests and mammography. The success of the NOCEDP is contingent upon collaboration and communication among the program participant, the referring physician and the NOCEDP staff. The referring physician will be notified of any abnormal test results. If you decide to participate in this research study, which requires signing a consent form, you will meet with a certified genetic counselor, an attending physician specializing in ultrasonography, and a board certified gynecologic oncologist.